The Latest Breaking News from Centene

Upgrades

Ahead of its investor day, Centene Corp (NYSE:CNC) increased its Premium and Service Revenues FY22 guidance range by $2.0 billion to $134.3 billion - $136.3 billion. The company also increased adjusted EPS guidance by $0.15 to $5.55 - $5.70 vs. the consensus of $5.49. The company's 2022 financial guidance has been updated to…

Over the past 3 months, 5 analysts have published their opinion on Centene (NYSE:CNC) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

BBC Panorama claims Operose Health uses physician associates, who are cheaper to employ than doctors, to assess patients

Centene's (NYSE:CNC) short percent of float has risen 7.87% since its last report. The company recently reported that it has 7.85 million shares sold short, which is 1.37% of all regular shares that are available for trading.

Centene (NYSE:CNC) has outperformed the market over the past 5 years by 5.11% on an annualized basis producing an average annual return of 14.96%. Currently, Centene has a market capitalization of $45.83 billion.

Centene (NYSE:CNC) has outperformed the market over the past 15 years by 12.83% on an annualized basis producing an average annual return of 19.78%. Currently, Centene has a market capitalization of $48.21 billion.

Over the past 3 months, 4 analysts have published their opinion on Centene (NYSE:CNC) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Upgrades

Centene Corporation (NYSE:CNC) has agreed to sell Magellan Rx to Prime Therapeutics LLC and PANTHERx Rare to a consortium of The Vistria Group, General Atlantic, and Nautic Partners.  Centene expects to receive approximately $2.8 billion in aggregate proceeds from the transactions. Magellan Rx is a comprehensive pharmacy solutions organization with specialty drug management, Medicaid administration, and comprehensive pharmacy…

US stock futures traded higher ahead of the much-awaited interest rate decision from the Federal Reserve. Investors, meanwhile, focused on some notable insider trades.